Literature DB >> 21893982

Interaction studies of an anticancer alkaloid, (+)-(13aS)-deoxytylophorinine, with calf thymus DNA and four repeated double-helical DNAs.

Zhenjia Liu1, Haining Lv, Hongyan Li, Yi Zhang, Haijing Zhang, Fuqin Su, Song Xu, Yong Li, Yikang Si, Shishan Yu, Xiaoguang Chen.   

Abstract

BACKGROUND: Phenanthroindolizidine alkaloids are a family of plant-derived compounds with significant antineoplastic activity. The specific biomolecular targets of these alkaloids have not yet been clearly identified. (+)-(13aS)-deoxytylophorinine is a new phenanthroindolizidine alkaloid originally extracted from the roots of Tylophora atrofolliculata and Tylophora ovata in our institute. (+)-(13aS)-deoxytylophorinine exerts both in vitro and in vivoanticancer activities.
METHODS: The in vivo anticancer effects and toxicity of this compound were investigated in mice, and interactions between this compound and double-helical DNA sequences were studied in detail with circular dichroic spectroscopy and fluorescence spectroscopy. Viscosity measurements were applied to check the interactive mode between this compound and DNA.
RESULTS: Potent anticancer effects were observed in vivo. Also, concentration-dependent interactions were observed and this compound seemed to interact in a sequence-specific manner with AT-repeated sequences of double-helical DNA. Such interactions were proved to be intercalating by viscosity measurements.
CONCLUSIONS: Anticancer alkaloid (+)-(13aS)-deoxytylophorinine can have sequence-specific interactions with DNA in an intercalating manner.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21893982      PMCID: PMC3709184          DOI: 10.1159/000329506

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  32 in total

1.  Spectroscopic study of the interaction of actinomycin D with oligonucleotides carrying the central base sequences -XGCY- and -XGGCCY- using multivariate methods.

Authors:  M Vives; R Tauler; R Eritja; R Gargallo
Journal:  Anal Bioanal Chem       Date:  2006-11-23       Impact factor: 4.142

2.  Recognition of B-DNA by neomycin--Hoechst 33258 conjugates.

Authors:  Bert Willis; Dev P Arya
Journal:  Biochemistry       Date:  2006-08-29       Impact factor: 3.162

3.  Circular dichroism to determine binding mode and affinity of ligand-DNA interactions.

Authors:  Nichola C Garbett; Patricia A Ragazzon; Jonathan B Chaires
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

4.  DNA bending and unwinding associated with actinomycin D antibiotics bound to partially overlapping sites on DNA.

Authors:  H Chen; X Liu; D J Patel
Journal:  J Mol Biol       Date:  1996-05-10       Impact factor: 5.469

5.  Thymidylate synthase activity in leukocytes from patients with chronic myelocytic leukemia and acute lymphocytic leukemia and its inhibition by phenanthroindolizidine alkaloids pergularinine and tylophorinidine.

Authors:  K Narasimha Rao; R K Bhattacharya; S R Venkatachalam
Journal:  Cancer Lett       Date:  1998-06-19       Impact factor: 8.679

6.  Characterization of a triple helix-specific ligand. BePI (3-methoxy-7H-8-methyl-11- [(3'-amino)propylamino]-benzo[e]pyrido[4,3-b]indole) intercalates into both double-helical and triple-helical DNA.

Authors:  D S Pilch; M J Waring; J S Sun; M Rougée; C H Nguyen; E Bisagni; T Garestier; C Hélène
Journal:  J Mol Biol       Date:  1993-08-05       Impact factor: 5.469

7.  Sequence and length dependent thermodynamic differences in heterocyclic diamidine interactions at AT base pairs in the DNA minor groove.

Authors:  Yang Liu; Arvind Kumar; David W Boykin; W David Wilson
Journal:  Biophys Chem       Date:  2007-09-06       Impact factor: 2.352

Review 8.  Analysing DNA complexes by circular and linear dichroism.

Authors:  B Nordén; T Kurucsev
Journal:  J Mol Recognit       Date:  1994-06       Impact factor: 2.137

9.  Quercetin is able to demethylate the p16INK4a gene promoter.

Authors:  Sainan Tan; Chong Wang; Cailing Lu; Baojian Zhao; Yi Cui; Xinquan Shi; Xu Ma
Journal:  Chemotherapy       Date:  2008-10-31       Impact factor: 2.544

10.  Construction of the plasmid for expression of ETA-EGFP fusion protein under control of the cytomegalovirus promoter and its effects in HeLa cells.

Authors:  Elena M Glinka; Alla S Andryushchenko; Alexander M Sapozhnikov; Olga V Zatsepina
Journal:  Plasmid       Date:  2009-06-13       Impact factor: 3.085

View more
  7 in total

1.  Challenges and Recent Advances of Novel Chemical Inhibitors in Medulloblastoma Therapy.

Authors:  Anand Maurya; Upendra Kumar Patel; Jitendra Kumar Yadav; Virender Pratap Singh; Alka Agarwal
Journal:  Methods Mol Biol       Date:  2022

2.  Synthesis, biological evaluation and mechanism studies of deoxytylophorinine and its derivatives as potential anticancer agents.

Authors:  Haining Lv; Jinhong Ren; Shuanggang Ma; Song Xu; Jing Qu; Zhenjia Liu; Qing Zhou; Xiaoguang Chen; Shishan Yu
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240

3.  CAT3, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O6-methylguanine DNA methyltransferase expression.

Authors:  Ming Ji; Liyuan Wang; Ju Chen; Nina Xue; Chunyang Wang; Fangfang Lai; Rubing Wang; Shishan Yu; Jing Jin; Xiaoguang Chen
Journal:  Onco Targets Ther       Date:  2018-06-25       Impact factor: 4.147

4.  Improving the Oral Bioavailability of an Anti-Glioma Prodrug CAT3 Using Novel Solid Lipid Nanoparticles Containing Oleic Acid-CAT3 Conjugates.

Authors:  Hongliang Wang; Lin Li; Jun Ye; Rubing Wang; Renyun Wang; Jinping Hu; Yanan Wang; Wujun Dong; Xuejun Xia; Yanfang Yang; Yue Gao; Lili Gao; Yuling Liu
Journal:  Pharmaceutics       Date:  2020-02-03       Impact factor: 6.321

5.  Improved Safety and Anti-Glioblastoma Efficacy of CAT3-Encapsulated SMEDDS through Metabolism Modification.

Authors:  Hongliang Wang; Lin Li; Jun Ye; Wujun Dong; Xing Zhang; You Xu; Jinping Hu; Rubing Wang; Xuejun Xia; Yanfang Yang; Dujia Jin; Renyun Wang; Zhihui Song; Lili Gao; Yuling Liu
Journal:  Molecules       Date:  2021-01-18       Impact factor: 4.411

6.  A novel and practical synthesis of CAT3: a phenanthroindolizidine alkaloid with potential in treating glioblastoma.

Authors:  Ru-Bing Wang; Hai-Ning Lv; Shan-Shan Zhu; Xiao-Dong Ren; Song Xu; Shuang-Gang Ma; Yun-Bao Liu; Jing Qu; Shi-Shan Yu
Journal:  RSC Adv       Date:  2018-08-17       Impact factor: 4.036

7.  Lipid-Based Nanocarriers for The Treatment of Glioblastoma.

Authors:  Nerea Iturrioz-Rodríguez; Rosalia Bertorelli; Gianni Ciofani
Journal:  Adv Nanobiomed Res       Date:  2020-11-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.